Definition:

◣

◢

BABYILY®Difucosyllactose Health Benefits:

BABYILY®Difucosyllactose (DFL) is an important component of human milk oligosaccharides (HMOs) and one of the simplest HMOs. DFL is a fucosylated HMO that promotes neonatal growth and development and possesses important antibacterial activities. DFL promotes neonatal growth and development and has important antibacterial activities.

■ Structural Characteristics

BABYILY®Difucosyllactose, also known as lacto-N-difucohexaose, is composed of two fucose sugars (Fuc), one glucose (Glc), and one galactose (Gal). These sugars are linked by an α-1,2-glycosidic bond. One of the fucose sugars is attached to the glucose sugar by an α-1,3-glycosidic bond. This forms a unique linear structure. The two fucoses are connected by α-1,2-glycosidic bonds. One fucose is attached to the glucose via an α-1,3-glycosidic bond. The glucose is connected to the galactose via a β-1,4-glycosidic bond, forming a unique linear structure. Due to glycosidic linkages and the stereochemical structure of the monosaccharides, DFL has a specific spatial configuration and are non-reducible.

Particularities of BABYILY®Difucosyllactose:

Product Specifications:

○

○

☑  BABYILY®Difucosyllactose 80%

Product quality standards:

● Novel Food, GRAS, Infant formula, In-housef

▶ Immune health

▶ Gut health

BABYILY®Difucosyllactose Applications:

BABYILY®Difucosyllactose can regulate the immune system through multiple pathways. For instance, DFL can stimulate the activity of intestinal mucosal immune cells, such as macrophages, T cells, and B cells. It can also promote the secretion of immunoglobulins, such as IgA, and enhance the mucosal immune response. Thus, DFL improves the body's resistance to pathogens.DFL's structure is similar to some receptors on intestinal epithelial cells. It competes with pathogens to bind to them, preventing them from adhering to intestinal cells. This reduces the chances of infection and provides a protective effect against common gastrointestinal infections in infants and young children. DFL has a protective effect against common gastrointestinal infections in infants and children.

BABYILY®Difucosyllactose cannot be broken down directly by human digestive enzymes, but it can serve as "food" for beneficial intestinal bacteria, promoting their growth. This proliferation can inhibit the growth of harmful bacteria, thereby maintaining the microecological balance of the intestinal tract and reducing the risk of infection. Improving the balance of intestinal flora can indirectly enhance the function of the intestinal mucosal barrier, reduce the amount of harmful substances that enter the bloodstream due to increased intestinal permeability, and lower the probability of intestinal inflammation and related diseases.

▶ Brain development

As a key component of breast milk oligosaccharides, BABYILY®Difucosyllactose can help infant formula more closely resemble the nutritional and functional properties of breast milk. This allows infants and young children who cannot be exclusively breastfed to achieve similar health benefits. DFL maintains intestinal health and bacterial balance, which indirectly promotes nutrient absorption and supports growth and development.

BABYILY®Difucosyllactose is available in the following specification and contents:

BABYILY®Difucosyllactose is often mixed with other breast milk oligosaccharides, such as 2'-fucosyllactose (2'-FL), and used in infant formula to resemble breast milk. This promotes the growth of beneficial intestinal bacteria in infants and children, balances intestinal flora, and enhances immunity.It can be added to children's probiotic beverages as a functional ingredient to maintain the balance of the product's ingredients while utilizing its prebiotic properties to promote children's intestinal health and regulate digestive function. It can also be added to children's lactic acid bacterial beverages to maintain the balance of specific ingredients and utilize its probiotic properties to promote intestinal health, regulate intestinal microecology, and enhance digestive function. In general, food products such as baked goods, dairy products, and beverages can use DFL as an ingredient to optimize texture or flavor.

■ Nutritional value

BABYILY®Difucosyllactose can act as a prebiotic for intestinal probiotics, maintaining intestinal microecological balance by promoting the growth of beneficial bacteria while inhibiting the growth of harmful bacteria. Human milk oligosaccharides (HMOs) are one of the key factors in establishing infant intestinal flora. DFL, as a representative HMO ingredient, can help artificially fed infants and young children mimic the intestinal regulatory effects of breast milk.

■ Production technology description

The production of BABYILY®Difucosyllactose is dominated by microbial fermentation combined with metabolic engineering and synthetic biology for efficient synthesis. This method uses multidimensional gene editing to integrate the α-1,2-fucosyltransferase (e.g., SAMT) and the α-1,3-fucosyltransferase (e.g., Fut3Bc) genes into a host, such as Escherichia coli. This process achieves two-step catalysis from lactose to 2'-FL to DFL. Overexpression of the GDP-L-fucose synthesis pathway gene and replacement of the natural promoter with a strong promoter efficiently supplies precursors. Knocking down the β-galactosidase (lacZ) and fucose catabolism (fcl) genes reduces lactose consumption and fucose loss, resulting in improved DFL purity. After optimizing the fermentation process (dynamic replenishment strategy and environmental parameter regulation) and the separation and purification technology (ceramic membrane filtration, weak cation exchange resin desalination, activated carbon column decolorization, and ethanol graded precipitation), the product was prepared as a powder using spray drying.

The microbial fermentation has become the core technology for DFL production due to its economy and scale-up potential, while enzymes and chemical synthesis complement specific needs.

General Information: